Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Cefetamet Pivoxil is a third-generation cephalosporin antibiotic administered orally, distinguished by its prodrug structure designed to enhance bioavailability. The chemical formula of Cefetamet Pivoxil is C21H25N5O8S2, and it is uniquely identified by the CAS number 74039-65-1. As a prodrug, it undergoes rapid hydrolysis in the gastrointestinal tract or plasma to release the active moiety, cefetamet, which is responsible for the therapeutic effect. This compound exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, making it particularly effective for treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media. Its mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby preventing peptidoglycan cross-linking and leading to cell lysis.
The development of the pivoxil ester group was crucial in overcoming the poor oral absorption associated with the parent cefetamet molecule. Once absorbed, the ester is cleaved enzymatically, ensuring high concentrations of the active drug reach systemic circulation and target tissues. Clinical studies have demonstrated its efficacy in treating infections caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, and Klebsiella species. Compared to earlier generations, Cefetamet Pivoxil offers improved stability against beta-lactamases produced by certain resistant organisms, although resistance mechanisms continue to evolve.
Safety profiles generally indicate that the drug is well-tolerated, with common adverse effects including gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Allergic reactions, ranging from mild rashes to severe anaphylaxis, remain a significant concern for patients with known hypersensitivity to cephalosporins or penicillins. Dosage regimens are typically adjusted based on renal function, as the drug is primarily excreted unchanged via the kidneys. Due to its specific pharmacokinetic properties and spectrum of activity, Cefetamet Pivoxil remains a valuable therapeutic option in clinical settings for managing various community-acquired infections where oral administration is preferred over intravenous therapy.